articles with this tag
MXC Moves Towards Commercial-Scale Pot Production with GMP Manufacturing Licence
Jul 13, 2018
Nimble ASX pot-stock MGC Pharmaceuticals (ASX:MXC) this week smashed a pivotal milestone, scoring full manufacturing licence for its world-class European compounding and manufacturing facility for the production of euGMP grade medicinal cannabis products.
CPH Continues to Expand Global Footprint As it Moves Into Israeli Cannabis Market
May 16, 2018
Creso Pharma (ASX:CPH) has today informed the market that it has entered into a joint venture with Cohen Propagation Nurseries Limited to operate a high quality medicinal cannabis growing facility in Israel.
MXC to Build Malta Production Facility to Capitalise on $55B Global Pot Market
Apr 12, 2018
MGC Pharmaceuticals (ASX:MXC) has wasted no time ramping up its game in 2018.
CPH Gets Green Light to Distribute its Innovative CBD Based Nutraceutical Products in the UK
Jan 18, 2018
While much of the business world shut down over the Christmas-New Year’s break, diversified cannabis healthcare company Creso Pharma (ASX:CPH) has been busy on a number of fronts.
CPH Seal Swiss Pharma Deal: Setting the Cornerstone for Global Commercialisation of cannaQIX
Dec 4, 2017
It has been a major month for Creso Pharma (ASX:CPH) as it continues to make potentially market moving announcements.
Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue
Nov 23, 2017
MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.
CPH to Acquire Canadian Cannabis Grower and Strengthen Position in Multi-Billion Dollar Market
Jul 27, 2017
Creso Pharma (ASX:CPH) is now in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc., an acquisition that would position CPH as a Canadian producer of legal cannabis.
CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release
Jun 14, 2017
News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.
CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation
May 2, 2017
Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.
Medical Marijuana Stock CPH Plants First Seeds in $800M Brazilian Market
Mar 22, 2017
There is no doubt about it – medical marijuana stocks are lighting up the ASX right now, as the mainstream media and investment community at large is finally starting to pick up on what we have been saying for over 12 months now.
Aussie Medical Cannabis Market Opens Up: CPH Takes Early Mover Advantage
Mar 1, 2017
Creso Pharma (ASX:CPH) is one company set to benefit from the Australian Federal Government’s move this month to improve access to medical cannabis and grant import/export licenses.
First Cannabis Revenues in Sight for CPH
Nov 7, 2016
The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.
Is a Cannabis Cultivation License Now Just Days Away for MMJ?
Jan 21, 2016
Last week a crucial piece of news hit emerging pharmaceutical company MMJ Phytotech (ASX:MMJ). In what is known as a ‘Pre-License Inspection’, Federal health inspectors at Health Canada will examine MMJ’s Canadian medicinal cannabis growing facilities.